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ARTICLE
A Chromosome 8 Gene-Cluster Polymorphism with Low Human
Beta-Defensin 2 Gene Copy Number Predisposes to Crohn
Disease of the Colon
Klaus Fellermann, Daniel E. Stange, Elke Schaeffeler, Hartmut Schmalzl, Jan Wehkamp,
Charles L. Bevins, Walter Reinisch, Alexander Teml, Matthias Schwab, Peter Lichter,
Bernhard Radlwimmer, and Eduard F. Stange
Defensins are endogenous antimicrobial peptides that protect the intestinal mucosa against bacterial invasion. It has
been suggested that deﬁcient defensin expression may underlie the chronic inﬂammation of Crohn disease (CD). The
DNA copy number of the beta-defensin gene cluster on chromosome 8p23.1 is highly polymorphic within the healthy
population, which suggests that the defective beta-defensin induction in colonic CD could be due to low beta-defensin–
gene copy number. Here, we tested this hypothesis, using genomewide DNA copy number proﬁling by array-based
comparative genomic hybridization and quantitative polymerase-chain-reaction analysis of the human beta-defensin 2
(HBD-2) gene. We showed that healthy individuals, as well as patients with ulcerative colitis, have a median of 4 (range
2–10) HBD-2 gene copies per genome. In a surgical cohort with ileal or colonic CD and in a second large cohort with
inﬂammatory bowel diseases, those with ileal resections/disease exhibited a normal median HBD-2 copy number of 4,
whereas those with colonic CD had a median of only 3 copies per genome ( for the surgical cohort;Pp .008 Pp .032
for the second cohort). Overall, the copy number distribution in colonic CD was shifted to lower numbers compared
with controls ( for both the surgical cohort and the cohort with inﬂammatory bowel diseases). Individuals withPp .002
3 copies have a signiﬁcantly higher risk of developing colonic CD than did individuals with 4 copies (odds ratio 3.06;
95% conﬁdence interval 1.46–6.45). An HBD-2 gene copy number of !4 was associated with diminished mucosal HBD-
2 mRNA expression ( ). In conclusion, a lower HBD-2 gene copy number in the beta-defensin locus predisposesPp .033
to colonic CD, most likely through diminished beta-defensin expression.
From the Department of Internal Medicine I, Robert-Bosch-Hospital (K.F.; H.S.; J.W.; E.F.S.), and Dr. Margarete Fischer-Bosch-Institute for Clinical
Pharmacology, (E.S.; M.S.) Stuttgart; Division of Molecular Genetics, German Cancer Research Center, Heidelberg (D.E.S.; P.L.; B.R.); Department of
Medical Microbiology and Immunology, University of California–Davis, Davis (J.W.; C.L.B.); and Department of Internal Medicine IV, Medical University
of Vienna, Vienna (W.R.; A.T.)
Received February 20, 2006; accepted for publication May 12, 2006; electronically published July 12, 2006.
Address for correspondence and reprints: Dr. Klaus Fellermann, Robert-Bosch-Hospital, Auerbachstrasse 110, 70376 Stuttgart, Germany. E-mail: klaus
.fellermann@rbk.de
Am. J. Hum. Genet. 2006;79:439–448.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7903-0007$15.00
Crohn disease (CD [MIM 266600]) is a severe chronic in-
ﬂammatory bowel disease characterized by intestinal ul-
ceration that affects predominantly the ileum and co-
lon.1,2 The cause of the disease is unknown. Recent ﬁnd-
ings have suggested that the mucosal immunological re-
action is directed against the resident bacterial ﬂora rather
than against tissue antigens.3 This loss of tolerance to the
normal ﬂora may be due to a dysregulation of the gut
mucosal immune response4 or, alternatively, a break in the
antibacterial barrier where microbiota can trigger a dele-
terious immune response.5
CD appears to be a consequence of both genetic and
environmental inﬂuences. The 50% concordance rate in
MZ twins, who often exhibit the same phenotype,6 sug-
gests a rather balanced impact of genetic and such envi-
ronmental factors as smoking7,8 or childhood hygiene.9
During a genomewide search, several susceptibility loci
and genes—including NOD2 (CARD15) (MIM 605956),10,11
DLG5 (MIM 604090),12 and OCTN (MIM 604190 and
603377)13—have been found to be associated with CD.
The best replicated is NOD2, which is involved in intra-
cellular sensing of bacterial muramyl dipeptide, promi-
nently expressed in macrophages and in particular small
intestinal Paneth cells.14,15 Despite these signiﬁcant ad-
vances, the multiple susceptibility loci and other genetic
factors hitherto identiﬁed16 do not satisfactorily explain
the inheritance rates.
The clinical syndrome of CD is variable with respect to
age at diagnosis, location (small and/or large intestine),
and disease behavior (inﬂammatory, stricturing, or pene-
trating disease). Therefore, these behavior parameterswere
used in the Vienna classiﬁcation,17 recently modiﬁed in
Montreal.18 Location of disease involvement proved to be
stable over time in individual patients, although the bio-
logical basis of small- versus large-intestinal involvement
is unclear. NOD2 mutations have been shown to be pre-
dominantly associated with ileal disease and have been
reported to be related to a relative lack of ileal Paneth-cell
alpha-defensins HD-5 (MIM 600472) and HD-6 (MIM
600471).19 Defensins are endogenous antibiotic peptides
that form a chemical barrier at the epithelial surface, and
their relative deﬁciency may lead to bacterial adherence
to the mucosa, slow invasion, and secondary mucosal
inﬂammation.5,20
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Table 1. Number of Patients in the Cohorts





CD: 85 54 111
Ileal (L1) 60 22 38
Colonic (L2) 25 10 36
Ileal and colonic (L3) 22 37
UC 38 37
In contrast to ileal disease, colonic CD is characterized
by an impaired induction of the epithelial beta-defensins
HBD-2 (MIM 602215), HBD-3 (MIM 606611), and HBD-
4.21–23 This relative deﬁciency of several beta-defensins is
unlikely to be explained by multiple coincident mu-
tations or other genetic alterations of all these genes.
Detailed studies of the defensin locus on chromosome
8 have uncovered an extensive DNA copy number poly-
morphism (CNP) of a gene cluster, including, among
others, the human beta-defensin genes HBD-2 (DEFB4),
HBD-3 (DEFB103), and HBD-4 (DEFB104).24 It has been
shown that the number of gene copies is positively cor-
related with the expression ofHBD-2 in leukocytes.24 Since
all these defensins were found to be coordinately under-
expressed in colonic CD,21 we hypothesized that this par-
ticular phenotype may be associated with a low beta-de-
fensin gene cluster copy number. We therefore measured
DNA copy number in the beta-defensin cluster in two in-
dependent cohorts with inﬂammatory bowel diseases and
related it to mucosal HBD-2 gene expression.
Material and Methods
Patients
The patients from three separate cohorts received diagnoses, with
use of the same standard criteria, in Cleveland, Stuttgart, and
Vienna and were treated in specialized tertiary-care out- and in-
patient centers. Patients gave their informed consent, and local
ethics committees approved the study protocols. A small cohort—
of patients with colonic CD ( ) and healthy control indi-np 10
viduals ( )—was recruited in Stuttgart. Their blood-derivednp 10
genomic DNA was subjected to the microarray analysis described
below. The exploratory cohort was a surgical group of patients
who underwent surgical resection at the Cleveland Clinic for
treatment of ileal or colonic Crohn disease (table 1). The conﬁr-
matory cohort were all whites with CD or ulcerative colitis (UC
[MIM 191930]) who were treated at the Robert-Bosch-Hospital
(Stuttgart) or the University Hospital (Vienna) (table 1). Diagnos-
tic and (Vienna) classiﬁcation criteria were the same at both Eu-
ropean centers.17 In this classiﬁcation, L1 is deﬁned as ileal disease
only, L2 as colonic disease only, and L3 as ileal as well as colonic
disease. Finally, the Stuttgart control group was combined with
blood donors ( ), individuals unaffected by inﬂammatorynp 103
bowel disease who underwent surveillance colonoscopy (np
), and 20 control individuals unaffected by intestinal disease46
from Cleveland. All colonoscopies that included biopsies were
performed on patients from the Stuttgart cohort.
Array CGH (Array-Based Comparative Genomic
Hybridization) Analysis
DNA preparation, labeling, hybridization, and analysis procedures
were performed as published elsewhere.25,26 In brief, genomic DNA
from fresh-frozen blood obtained from 10 patients with colonic
CD and from 10 healthy control individuals was isolated using
the Blood andCell Culture Kit (Qiagen) following the instructions
of the supplier. Sample DNA and reference DNA (pooled DNA
from six healthy individuals) were labeled differentially with use
of the Bioprime Labelling Kit (Invitrogen) and were hybridized
on a DNA microarray consisting of ∼8,000 genomic fragments
covering the human genome at a resolution of ∼0.5 Mb.27 For
the beta-defensin locus at 8p23.1, all additional genomic frag-
ments that were available at the time were added to the micro-
array to enhance the resolution in the region of interest. The
chromosomal mapping information was based on the Ensembl
Genome Browser release 36.35i (December 2005). Arrays were
scanned, and ﬂuorescence intensities of all spots were ﬁltered
(intensity/local background 13; mean/median intensity !1.3; SD
of genomic fragment log ratios !0.25) andwere normalizedblock-
wise. Chromosomal breakpoints delimiting regions of different
copy number status were detected by GLAD (gain and loss anal-
ysis of DNA).28
Determination of HBD-2 Gene Copy Number
A TaqMan real-time PCR assay, speciﬁcally for ampliﬁcation of
genomic HBD-2, was established by using a speciﬁc set of am-
pliﬁcation primers (forward 5′-CACCTGTGGTCTCCCTGGAA-3′;
reverse 5′-AGCTTCTTGGCCTCCTCATG-3′) and a probe (6-FAM-
ATGCTGCAAAAAG-MGB). Quantitative HBD-2 ampliﬁcation data
were normalized to ALB (albumin [MIM 103600]) as an internal
reference gene, which was coampliﬁed simultaneously in a single-
tube biplex assay. The primers and probe forHBD-2were designed
using Primer Express software, version 1.5 (Applied Biosystems).
For albumin, we used the primers and probe that were published
elsewhere.29 Primers were purchased from MWG-Biotech, and
probes were obtained from Applied Biosystems. Real-time PCR
was performed using the ABI Prism 7700 sequence-detection sys-
tem. Ampliﬁcation reactions (25 ml each) were performed in trip-
licate with 20 ng of template DNA, 1# TaqMan Universal Master
Mix buffer (Applied Biosystems), 300 nM of each primer, and 200
nM of each ﬂuorogenic probe. Thermal cycling was initiatedwith
a 2-min incubation at 50C, followed by a ﬁrst denaturation step
of 10 min at 95C and then by 40 cycles for 15 s at 95C and for
1 min at 60C. In each assay, a standard curve was recorded and
a no-template control was included. To amplify HBD-2 and al-
bumin in a one-tube biplex assay, limiting primer conditionswere
identiﬁed, to avoid competition of the two reactions. Quantiﬁ-
cation was performed by both the standard-curve method and
the comparative CT (threshold cycle) method, as described else-
where.29 The assay was validated with a selection of DNA samples,
genotyped elsewhere (kindly provided by E. J. Hollox, Notting-
ham, United Kingdom), that contained 3, 4, 5, and 7 HBD-2 gene
copies.24
Real-Time Quantitative PCR
Frozen biopsies were disrupted in 1 ml of Trizol (Gibco BRL) until
complete fragmentation occurred. Total RNA was extracted ac-
cording to the supplier’s protocol. RNA quality was determined
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by electrophoresis and was quantiﬁed by photometry. Subse-
quently, 2 mg of RNA was reverse transcribed with oligo-dT prim-
ers and 200 U Superscript (Gibco BRL), according to the routine
procedure.
cDNA samples were subjected to real-time PCR as outlined else-
where.21 In brief, an aliquot corresponding to 50 ng of RNA was
set up in a 20-ml reaction mixture containing 4 mM MgCl2, 0.5
mM of each primer (for HBD-2, forward 5′-ATCAGCCATGAGG-
GTCTTGT-3′ and reverse 5′-GAGACCACAGGTGCCAATTT-3′ [an-
nealing temperature 60C; product 172 bp]; for HBD-3, forward
5′-TGAAGCCTAGCAGCTATGAGGATC-3′ and reverse 5′- CCGCC-
TCTGACTCTGCAATAA-3′ [annealing temperature 62C; product
128 bp]; for interleukin 8 [IL-8 (MIM 146930)], forward5′-ATGACT-
TCCAAGCTGGCCGTGGC-3′ and reverse 5′-TCTCAGCCCTCTT-
CAAAAACTTC-3′ [annealing temperature touch down protocol
66C–60C; product 292 bp] [Sigma]) and 1# LightCycler-Fast-
Start DNA Master SYBR Green I Mix (Roche Molecular Biochemi-
cals) and was loaded in capillary columns. PCR was performed
for 45 cycles in a LightCycler (Roche Molecular Biochemicals).
After each cycle, ﬂuorescence emission readings reﬂecting the
increase in PCR products were monitored and analyzed using
LightCycler software (Roche Molecular Biochemicals).
DNA Sequencing
Exons 1 and 2 of the HBD2 gene and ∼50 bp of adjacent non-
coding regions were PCR ampliﬁed from genomic DNA and were
sequenced on an Applied Biosystems 3100 capillary sequencer
with use of Big-Dye chemistry. The sequences of the ampliﬁcation
and nested sequencing primers are available on request.
Statistics
Statistical comparisons of copy numbers of (1) ileal and colonic
subsets in the Cleveland cohort as well as (2) patients with L1,
L2, and L3 UC and (3) control individuals from the European
collective were performed with the (two-sided) Mann-Whitney
test. Additionally, Kruskal-Wallis analysis of variance of ranks,
including post hoc assessment by Dunn’s test, was performed to
correct for multiple testing. Differences in copy number distri-
bution among the clinical cohorts were assessed by the Pearson
x2 test, with continuity corrections. Again, the Mann-Whitney
test was used to assess differences in HBD-2 mRNA expression
with increasing HBD-2 gene copy numbers.
Results
Microarray Analysis
Using an array CGH with ∼8,000 genomic fragments cov-
ering the human genome, with an average resolution of
∼0.5 Mb, we screened 10 patients with colonic CD and
10 healthy control individuals for DNA copy number var-
iations. No gross chromosomal aberrations were present
in either group (data not shown), but we detected several
known regions of CNP, such as the IGHG1 gene cluster at
14q32.33 (MIM 147100) (data not shown) or the amylase
gene cluster at 1p21.1 (MIM 104700) (ﬁg. 1A). Except for
the beta-defensin gene cluster at 8p23.1 (ﬁg. 1B), however,
no region showed a bias toward copy number loss or gain
in patients versus controls. In the EnsemblGenomeBrowser
(release 36.35i), the beta-defensin cluster is shown to be
organized as a pair of inverted repeats separated by a se-
quence gap (ﬁg. 1C). This probably represents theminimal
size of the locus in humans. In the patient and control
samples that showed copy number variation compared
with the control DNA, the size of the variable region was
always the same, covering ∼900 kb (megabase 7.1–8.0),
including BAC clones RP11-278P18, RP11-1005B13, and
RP11-52B19 (Clone Registry). This region contains both
copies of the beta-defensin cluster but not the alpha-de-
fensin cluster, as is shown for patient X1604 in ﬁgure 1C.
When comparing the copy number proﬁles of the patient
and control groups, it became evident that patients with
CD, on average, seemed to have fewer copies than did
healthy individuals. Relative to aDNApool from6healthy
control individuals, 8 of 10 patients with CD displayed
small copy number losses, and none displayed copy num-
ber gains (ﬁg. 1D). In control individuals, no such bias
was observed (ﬁg. 1E). Theneighboringalpha-defensingene
cluster (ﬁg. 1C), whichmapped tomegabase 6.76–6.90, and
other beta-defensin–like loci—identiﬁed on chromosomal
bands 6p12, 20q11.1, and 20p13 by sequence similarity
search30—did not show any copy number variation in pa-
tients or control individuals (data not shown).
HBD-2 Gene Copy Numbers in Inﬂammatory Bowel
Diseases
Our array CGH analyses clearly indicated that low DNA
copy number at the main beta-defensin locus might be
connected to CD; however, the size of this initial sample
was much too small for reliable correlation analysis. Fur-
thermore, whereas array CGH is extremely useful forwhole-
genome scans, its quantitative performance is suboptimal
at loci that are rich in low copy number DNA repeats
(LCRs), such as the beta-defensin cluster. At such loci, the
reported copy number ratios can be severely affected by
cross-hybridization of the LCRs.25
Therefore, we decided, as an alternative, to use quanti-
tative PCR analysis of theHBD-2 gene to estimate theDNA
copy number of the beta-defensin cluster. This HBD2
gene–speciﬁc approach was applied to a control popula-
tion and to two patient cohorts, one from the United
States and one from Europe (table 1). In the control pop-
ulation ( ) the copy numbers had a range of 2–10np 169
per genome, with a median number of 4 copies (ﬁg. 2A).
The numbers of control individuals who carry themedian
(4), below-median (!4), or above-median (14) number of
copies were about equal. Details of the copy number fre-
quencies of all cohorts and subgroups are given in table
2.
The U.S. patient cohort from the Cleveland Clinic con-
sisted of 85 surgical patients with CDwho had indications
for ileal versus colonic resection. In patients with ileal re-
sections (ﬁg. 2B), the median number of copies was iden-
tical to that of the control group (4 copies); also, the fre-
quency distribution of the three subgroups (with !4, with
4, and with 14 gene copy numbers) was not signiﬁcantly
442 The American Journal of Human Genetics Volume 79 September 2006 www.ajhg.org
Figure 1. A, Copy number ratios of ∼8,000 clones covering the whole genome, with a resolution of ∼0.5 Mb, are shown for patient
X1604. The loci of the amylase and beta-defensin gene clusters are indicated. The red lines in panels A and B show the smoothed copy
number ratio, as calculated by the GLAD algorithm. B, Copy number ratios of all clones on chromosome 8 of patient X1604. The beta-
defensin locus on 8p23.1 is indicated. C, Detail of copy number ratios on 8p23.1 for patient X1604. The alpha-defensin and the two
beta-defensin loci are shown by arrows, indicating the genomic orientation of the loci; “sequence gap” indicates a region where no
human reference sequence is available. The genomic position, length, and name of genomic fragments covering the region of interest
are displayed at the top. The red line indicates the average genomic position of the region that shows a CNP in our 20 hybridizations.
D, Copy number ratios in the 8p23.1 region of 10 patients with colonic CD. E, Copy number ratios in the 8p23.1 region of 10 healthy
control individuals.
different from that of the control group. In contrast, the
majority (72%) of patients with colonic resections had a
copy number !4, with a median of 3 copies (ﬁg. 2C). The
difference in copy numbers was highly signiﬁcant (Pp
[Mann-Whitney]) between the ileal and colonic sub-.008
groups with CD. This was maintained when tested by
Kruskal-Wallis analysis of variance ( for both postP ! .01
hoc Dunn test ileal vs. colonic and colonic vs. control).
Similarly, the proportion of the three copy number groups
in the two subgroups with CD was signiﬁcantly different
( [Pearson x2]).Pp .018
An independent second cohort of Europeanpatientswith
CD ( ) from Stuttgart and Vienna was classiﬁed ac-np 165
cording to the Vienna classiﬁcation of location into those
with ileal disease only (L1), with colonic disease only (L2),
or with ileal plus colonic disease (L3). Again, ileal CD (L1)
exhibited a copy number distribution similar to controls
( ), with a majority in the group with 4 gene copiesP 1 .05
(ﬁg. 3). The median was 4 copies in L1 and controls com-
pared with 3 in L2 ( and , respectivelyPp .032 Pp .001
[Mann-Whitney]). Analysis of variance and post hoc test
identiﬁed a signiﬁcant difference between L2 and controls
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Figure 2. Distribution of HBD-2 gene copy numbers in the 169
controls from Stuttgart and Cleveland (A) and both surgical CD
cohorts with ileal (B) and colonic resection (C) allocated to !4,
4, or 14 copies per genome. The difference in distribution between
ileal and colonic resection was signiﬁcant ( [x2 test]).Pp .018
Table 2. HBD-2 Gene Copy Number Frequencies
Cohort
Percentage of Cohort with
HBD-2 Gene Copy Number of
2 3 4 5 6 7 8 9 10
Control:
Cleveland 5.0 15.0 45.0 25.0 5.0 5.0
Europe 2.7 23.5 38.3 23.5 10.1 .7 .7 .7
Cleveland:
Ileal 1.7 36.7 35.0 20.0 6.7
Colonic 12.0 60.0 16.0 8.0 4.0
European:
L1 5.0 23.3 43.3 21.7 1.7 5.0
L2 2.2 50.0 32.6 10.9 2.2 2.2
L3 8.5 32.2 35.6 15.3 5.1 3.4
UC 5.3 33.3 33.3 14.7 9.3 2.7 1.3
NOTE.—For the number of patients in these subgroups, see table 1.
only ( ). Colonic CD only (L2) was characterized byP ! .05
a shift to lower copy numbers, with the majority (52%)
carrying !4 copies of HBD-2 ( vs. controls;Pp .002 Pp
vs. L1 [Pearson x2]). Individuals with 3 copies have.037
a signiﬁcantly higher risk of developing colonic CD than
do individuals with 4 copies (odds ratio 3.06; 95% CI
1.46–6.45). Patients with L3 showed an intermediate dis-
tribution pattern between controls and L2, and, although
the median was the normal 4 copies, the shift in distri-
bution was signiﬁcant ( [Mann-Whitney]). InUC,Pp .034
differences with controls were not signiﬁcant. Detailed
noncategorized copy number data are given in table 2.
HBD-2 Expression Related to HBD-2 Gene Copy Numbers
in Inﬂamed Mucosa
Mucosal biopsies were analyzed for HBD-2, HBD-3, and
IL-8 expression in patients from the Stuttgart cohort. Since
HBD-2 expression is negligible in normal mucosa but is
enhanced during inﬂammation, the biopsy samples were
taken from a subgroup of 44 patients with inﬂammation
due to CD ( ) or UC ( ). HBD-2 and HBD-3np 17 np 27
expression was highly correlated ( in CD;rp 0.84 rp
in UC). When themucosal mRNA expression ofHBD-0.86
2 was related to the HBD-2 gene copy number in the same
patients (ﬁg. 4),HBD-2mRNA expressionwas signiﬁcantly
diminished in the group with !4 compared with 4 copies
( [Mann-Whitney]) or 4 ( ), whereas IL-Pp .023 Pp .033
8 expression in these copy number groups was not sig-
niﬁcantly different (data not shown).
HBD-2 Gene Sequencing
Finally, to investigate the possibility that HBD-2 gene ex-
pression might be affected by the presence of gene copies
that are inactivated by point mutations, we sequenced
exon 1 and exon 2 of the HBD-2 gene in eight patients
with colonic CD and eight control individuals.We did not
ﬁnd any nonsense or missense mutations in the coding
region. The only sequence variations present were one
synonymous SNP in exon 2 (rs2740090) and four SNPs in
noncoding sequences (rs2740086, rs2740091, rs2737912,
and rs2737913). These SNPs occurred without predomi-
nance in either patients or control individuals (data not
shown; SNPs were retrieved from dbSNP).
Discussion
CNPs and their effect on phenotypic variation and disease
recently have become a major focus of attention.31–33 At
present, 1200 loci of large-scale CNPs have been detected
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Figure 3. Distribution of HBD-2 gene copy numbers (!4, 4, or 14 copies per genome) in the European cohort as categorized into
ileal disease (L1) (A), colonic disease (L2) (B), ileal and colonic disease (L3) (C), and UC (D). L2 (colonic CD) differed signiﬁcantly
from L1 (ileal CD) and controls ( and , respectively [x2 test]).Pp .037 Pp .002
using BAC arrays (Clone Registry)32,33 or oligonucleotide
arrays.31 With use of SNP genotyping data, recent studies
have found ∼1,000 ﬁne-scale deletion variants in the hu-
man genome.34–36 The role of these genetic alterations and
their impact on disease or disease susceptibility is not clear.
Several examples show that copy number alterations can
lead to altered gene expression and disease; for example,
copy number increase at the alpha-synuclein locus (4q21
[MIM 163890]) causes Parkinson disease (MIM 168600),37
and duplication of PMP22 (17q11.2 [MIM 601097]) causes
Charcot-Marie-Tooth disease (MIM 118220).38 Recently, a
study showed that some cases of early-onset Alzheimer
disease (MIM 104300) resulted from a duplication of the
APP locus (MIM 104760).39 CNPs can also lead to disease
susceptibility, which was shown, for example, for the pos-
session of a low copy number of the CCL3L1 gene (MIM
601395) that is associated with markedly enhanced HIV/
AIDS (MIM 609423) susceptibility.40 GeneCNPs,which are
associated with variable drug response, have also been de-
scribed for drug-metabolizing enzymes. For example, in-
herited ampliﬁcation of an active gene in the cytochrome
P450 CYP2D locus is a cause of ultrarapid metabolism of
debrisoquine.41 We have recently reported the development
of an RT-PCR–based assay to genotype CYP2D6 (MIM
124030) with respect to its gene copy number,29 similar
to the technique used in the present study. A previous
study of beta-defensin gene copy number in cystic ﬁbrosis
(MIM 219700) had negative results.42
Recently, the ﬁnished sequence and a gene catalogue of
chromosome 8 were reported.43 A unique feature of the
chromosome is a vast region of ∼15 Mb on distal 8p that
appears to have a strikingly high mutation rate. Within
this region, the CNPs in the defensin cluster on chromo-
some 8p23.1 are of special interest, since they may be
linked to immune function and disease. The copy number
variation in this region is complex, with two different
clusters of defensins—alpha- and beta-defensins—appar-
ently showing an independent variation of their copy
numbers.44 In the alpha-defensin cluster, the genes DEFA1
(MIM 125220) andDEFA3 (MIM 604522) code for the neu-
trophil defensins HNP-1 and HNP-3, respectively. Their
copy numbers, with a range of 5–14, were related to neu-
trophil HNP 1–3 levels.44 In contrast, copy numbers of
DEFA5 (MIM 600472) and DEFA6 (MIM 600471)—coding
for the alpha-defensins HD-5 and HD-6, respectively—ap-
pear to be stable, with two per diploid genome.44 This was
also conﬁrmed for the patients with CD, which suggests
that the low HD-5 and HD-6 levels in ileal CD are not
related to low copy numbers.45
Prompted by the diminished induction of beta-defen-
sins in the colonic mucosa of patients with CD compared
with patients with UC,21–23 we asked whether the copy
numbers in the variable beta-defensin locus were lowwith
respect to those in both healthy control individuals and
subjects with inﬂammatory bowel disease (UC and ileal
CD). The initial experiments, with use of high-resolution
array CGH for genomic copy number proﬁling, suggested
that, compared with controls. there indeed was a lower
copy number of the beta-defensin locus in patients with
colonic CD. All other regions of CNPs covered by the mi-
croarray showed equal copy number distributions between
patients with colonic CD and control individuals. A se-
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Figure 4. HBD-2 mRNA expression, with respect to HBD-2 gene
copy number, in mucosal specimens from patients with CD and UC
with rectal inﬂammation.
quencing approach of theHBD-2 gene in a limitednumber
of patients with colonic CD and control individuals re-
vealed several known SNPs but no nonsense or missense
mutations. None of the SNPs was preferentially found in
either patients or control individuals. Further haplotype
analysis of the HBD-2 gene was not performed because of
the immense difﬁculties of such analyses.46
It might seem surprising that the beta-defensin locus on
chromosome 8 has not been identiﬁed in any of the pre-
vious linkage studies,10,11 in particular since deletions re-
cently were shown to be in linkage disequilibrium with
SNPs.35 The relevance of this ﬁnding for the present study
is questionable, however, since the beta-defensin cluster
consists of multiple gene copies and is expected to be
much less stable than a simple deletion. Therefore, it is
not clear whether gene CNPs are at all detectable by link-
age analyses. Furthermore, previous studies might have
overlooked a possible linkage, since they did not distin-
guish colonic and ileal CD.
Since DNAmicroarrays allow full coverage of thehuman
genome but are less suitable for high-throughput studies
in large patient cohorts, we developed a real-time PCR-
based technique to quantitate HBD-2 copy number vari-
ations. Since HBD-2 and HBD-3 copy numbers covary in
tandem, it may be assumed that themeasuredHBD-2 copy
number reﬂects the whole beta-defensin gene cluster.24,44
This is also consistent with the close correlation of HBD-
2 and HBD-3 expression demonstrated in the present and
a previous study.21 A similar PCR-based technique was re-
cently published by Chen et al.47 The normalmedian num-
ber of 4 copies found in the present study conﬁrms the
ﬁnding of Chen et al.47 and that of Hollox et al.42 but is
slightly lower than the median of 5 observed by Linzmeier
et al.44
Since the surgical patients with CD usually have a par-
ticularly severe disease course, we ﬁrst studied patientswith
ileal versus colonic resections as typical phenotypes. A
clear-cut difference by 1 gene copy was observed and was
then conﬁrmed in a second, larger cohort of patients clas-
siﬁed clinically according to the Vienna classiﬁcation.17
We focused on localization as a stable factor during the
disease course and noted that the patient cohort with co-
lonic disease experienced a shift to lower copy numbers.
Although this shift was signiﬁcant, there was clearly an
overlap between the groups, which suggests that addi-
tional, still unknown factors of genetic or environmental
origin impact CD. Interestingly, patients with both ileal
and colonic CD (L3) had an intermediate copy number
distribution.
Notably, this relatively small difference in HBD-2 copy
numbers appeared to have an inﬂuence on mucosal HBD-
2 expression by gene dosage effect,48 which was signiﬁ-
cantly higher in patients with 4 compared with thosewith
fewer gene copies. The biological consequence will likely
be an impaired antimicrobial defense in individuals with
!4 copies. This is consistent with the previous ﬁnding of
Hollox et al.24 that HBD-2 expression in lymphoblastoid
cell lines was correlated linearly with theHBD-2 gene copy
number in the range of 2–7 copies. In some contrast, we
did not observe a linear increase in the higher range of
copy numbers 14, which may be related to the present
complex patient situation in which many other factors,
including bacterial ﬂora and inﬂammation, may affect de-
fensin expression. Alternatively, the plateau in defensin
gene expression we observe at copy numbers of4 might
be due to some unknown mechanism limiting gene ex-
pression in the native colon tissue, which might not be
active in lymphoblastoid cells. At any rate, despite these
confounding factors, the gene dosage effect on HBD-2 ex-
pression prevailed for low-to-normal copy numbers.
In conclusion, the low beta-defensin gene copy number
in CD was clearly associated with colonic disease localiza-
tion—that is, a speciﬁc phenotype of CD. A normal beta-
defensin copy number distribution was seen in CD of the
ileum and also in UC. This study may provide the genetic
basis for the diminished induction of beta-defensins in
colonic CD compared with UC in which colonic beta-
defensin induction is intact, as described elsewhere.21–23
We suggest that the antibacterial barrier in the colonic
mucosa is weakened because of relative defensin deﬁ-
ciency in colonic CD. This ﬁnding complements our pre-
vious report of a diminished alpha-defensin synthesis in
ileal CD, which was further pronounced with a concom-
itant NOD2 mutation.19,45 This differential compromise of
the complex defensin system may explain the different
phenotypes of colonic versus ileal CD20,49 as well as the
observation that bacteria of the normal ﬂora adhere and
sometimes invade the epithelium in CD.50–52 Possibly, this
barrier problem triggers the chronic inﬂammation known
as CD.
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